Search

Copyright of Imaging Science & Photochemistry is the property of Imaging Science & Photochemistry Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Experimental Technology & Management is the property of Experimental Technology & Management Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

This study explored the evaluation of 18F-fluorodeoxyglucose positron emission computed tomography/computed tomography (18F-FDG PET/CT) technology for the evaluation of type 2 diabetes (T2DM) on the programmed death receptor-1 ligand in patients with advanced colorectal cancer (PD-L1) The effect of treatment efficacy. A total of 104 patients with advanced colorectal cancer were selected, and they were divided into T2DM group (n = 49) and no T2DM group (n = 55) according to whether they were accompanied by T2DM. The efficacy and 18F-FDG PET/CT technical parameters: average standard uptake value (SUVmean)t maximum standard uptake value (SUVmax)t metabolic volume (MTV), total glycolysis of lesions (TLG) were compared between the two groups, and the application value of 18F-FDG PET/CT were explored. The results showed that the pathological staging, curative effect, SUVmean, SUVmaX, MTV, TLG of the T2DM group were compared with those without T2DM, and the difference was statistically significant (P<0. 05); T2DM and T2DM without remission were SUVmean, SUVmax, MTV, TLG SUVmean, SUVmax, MTV, and TLG in the T2DM group were higher than those in the non-T2DM group (P< 0. 05). SUVmean, SUVmax, MTV, and TLG were negatively correlated with the efficacy (P<0. 05). SUVmean, SUVmax, MTV combined with TLG predict the highest value of T2DM unrelief. The combined detection of SUVmean, SUVmax, MTV, and TLG with 18F-FDG PET/CT technology can evaluate the effect of T2DM on the efficacy of PD-L1 targeted therapy in patients with advanced colorectal cancer, and can objectively and quantitatively predict the patient's response to treatment. [ABSTRACT FROM AUTHOR]

Objective To analyze the detection of sarcoidosis on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography (,SF-FDG PET/CT). Methods Clinical and pathological data as well as PET/CT of 35 patients (21 women and 14 men, age range: 34-78 years, mean 45 ±10 years) with histologically confirmed sarcoidosis from 2015 to 2019 in our hospital were analyzed retrospectively. Results The clinical manifestations included cough (29), chest tightness and shortness of breath (22), chest pain (4), fever (3), superficial lymph node enlargement (3), and joint pain (1). PET/CT showed bilateral hilar, (34/35, 97.14%), mediastinal (33/35, 94.28%), right hilar (1/35, 2.86%), cervical (2/35, 5.71%), or abdominal (2/35, 5.71%) lymphadenopathy with increased FDG uptake, bilateral multiple or diffuse lung nodules (19/35, 54.29%), lung consolidation (3/35, 8.57%), pulmonary ground glass opacities (2/35, 5.71%), interstitial lung fibrosis (2/35, 5.71 %), enlargement of tracheal blood vessels (16/35, 45.71%), pleural effusion (3/35, 8.57%), pericardial effusion (1/35, 2.86%), increased uptake in the diaphragm cnira (1/35, 2.86%) and hepatic caudate lobe (1/35, 2.86%). Histology showed typical non-caseous necrotizing granulomatous lesions with negative specific staining in all patients by transbronchial lung biopsy (16), endobronchoscopic ultrasound-guided transbronchial needle aspiration (11), percutaneous lung biopsy (3), superficial lymph node biopsy (3), or tlioraco.scopic suigery (2). Conclusion The clinical manifestations of sarcoidosis are diverse and nonspecific. PET/CT can aid diagnosis and depict active lesions. [ABSTRACT FROM AUTHOR]

Copyright of Clean Coal Technology is the property of Clean Coal Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To evaluate the value of PET/CT in preoperative assessment and postoperative monitoring of ovarian cancer. Methods A retrospective analysis was conducted in 45 patients of ovarian neoplasm with clinical records underwent18F-FDG PET/CT, including 10 patients underwent PET/CT before surgery and 35patients after surgery. The clinical follow-up time was 6 months at least. The diagnosis based on pathology and clinical follow-up data. Results(1) The sensitivity, specificity and accuracy of PET/CT in detecting ovarian cancer were94.6%,75.0% and 91.1%, respectively.(2) Ten patients before surgery were all detected tumor by PET/CT,but 2 of them were false positive based on pathologic results.(3) Two patients with non-standard surgery were detected tumor by PET/CT. In 33 patients after standard surgery, 6 patients were no tumor detected by PET/CT. In addition,4 patients with normal CA125 and no signs of recurrence and metastasis were detected tumor by PET/CT.The pathology and clinical follow-up data supported the results. 23 patients with higher CA125 were diagnosed recurrence and metastasis based on pathology and clinical follow-up data,21 of them were detected tumor by PET/CT. Conclusion18F-FDG PET/CT plays an important role in preoperative assessment, early diagnosis and accurate positioning of recurrent and metastasis of ovarian cancer. It can be used to guide the clinical treatment. [ABSTRACT FROM AUTHOR]